Healthcare / Diagnostics & ResearchBSE
$7.52
+0.35 (+4.88%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-597100.00 · quality 47.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$114M
P/E
376.0x
↑EV/EBITDA
75.8x
↑ROE
0.4%
↑Gross Margin
86.8%
↑Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+7.1%
FCF CAGR
—
FCF margin
-42.4%
FCF / Net income
-7.59x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.5M · net income $419000.0 · FCF $-3.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.5M | $7.5M | $7.8M | $6.8M | $6.1M |
| Net Income | $419000.00 | $419000.00 | $-338000.00 | $-1.0M | $-1.2M |
| EBITDA | $1.6M | $1.6M | $417800.00 | $-403165.67 | $-456081.80 |
| EPS | — | — | -0.02 | -0.07 | -0.08 |
| Gross Margin | 86.8% | 86.8% | 85.2% | 83.7% | 85.0% |
| Operating Margin | 4.5% | 4.5% | -7.4% | -18.1% | -23.6% |
| Net Margin | 5.6% | 5.6% | -4.3% | -15.3% | -20.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.09 | 0.08 | 0.07 |
| Current Ratio | 2.22 | 2.22 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.2M | $-3.2M | $-597100.00 | $-450100.00 | $-5.00 |
| Returns | |||||
| ROE | 0.4% | 0.4% | -0.3% | -1.0% | -1.2% |
| Valuation | |||||
| P/E | 376.00 | 376.00 | — | — | — |
| EV/EBITDA | 75.82 | 75.82 | 111.31 | — | — |
| P/B | 1.13 | 1.13 | 0.38 | 0.37 | 0.23 |
| Growth & Yield | |||||
| Revenue Growth | -3.8% | -3.8% | 14.9% | 11.0% | — |
| EPS Growth | — | — | 71.4% | 15.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+228.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → n/d
Residual
+228.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.